tetano
Editor, Senior Moderator
Sci Rep
. 2023 Apr 20;13(1):6497.
doi: 10.1038/s41598-023-33682-2.
Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study
Pilar Irún[SUP] 1 2 [/SUP], Rafael Gracia[SUP] 3 [/SUP], Elena Piazuelo[SUP] 4 5 6 7 [/SUP], Julián Pardo[SUP] 5 8 9 10 [/SUP], Elena Morte[SUP] 5 10 11 [/SUP], José Ramon Paño[SUP] 5 10 11 [/SUP], Julio Boza[SUP] 3 [/SUP], Patricia Carrera-Lasfuentes[SUP] 4 5 [/SUP], Gustavo A Higuera[SUP] 3 [/SUP], Angel Lanas[SUP] 4 5 12 13 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is highly heterogeneous, ranging from asymptomatic to severe and fatal cases. COVID-19 has been characterized by an increase of serum pro-inflammatory cytokine levels which seems to be associated with fatal cases. By contrast, the role of pro-resolving lipid mediators (SPMs), involved in the attenuation of inflammatory responses, has been scarcely investigated, so further studies are needed to understand SPMs metabolism in COVID-19 and other infectious diseases. Our aim was to analyse the lipid mediator metabolome, quantifying pro- and anti-inflammatory serum bioactive lipids by LC-MS/MS in 7 non-infected subjects and 24 COVID-19 patients divided into mild, moderate, and severe groups according to the pulmonary involvement, to better understand the disease outcome and the severity of the pulmonary manifestations. Statistical analysis was performed with the R programming language (R Foundation for Statistical Computing, Vienna, Austria). All COVID-19 patients had increased levels of Prostaglandin E[SUB]2[/SUB]. Severe patients showed a significant increase versus controls, mild- and moderate-affected patients, expressed as median (interquartile range), in resolvin E1 [112.6 (502.7) vs 0.0 (0.0) pg/ml in the other groups], as well as in maresin 2 [14.5 (7.0) vs 8.1 (4.2), 5.5 (4.3), and 3.0 (4.0) pg/ml, respectively]. Moreover, 14-hydroxy docosahexaenoic acid (14-HDHA) levels were also increased in severe vs control and mild-affected patients [24.7 (38.2) vs 2.4 (2.2) and 3.7 (6.4) ng/mL, respectively]. Resolvin D5 was also significantly elevated in both moderate [15.0 (22.4) pg/ml] and severe patients [24.0 (24.1) pg/ml] versus controls [0.0 (0.0) pg/ml]. These results were confirmed by sparse partial least squares discriminant analysis which highlighted the contribution of these mediators to the separation between each of the groups. In conclusion, the potent inflammatory response to SARS-CoV-2 infection involves not only pro- but also anti-inflammatory lipid mediators that can be quantified in easily accessible serum samples, suggesting the need to perform future research on their generation pathways that will help us to discover new therapeutic targets.
. 2023 Apr 20;13(1):6497.
doi: 10.1038/s41598-023-33682-2.
Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study
Pilar Irún[SUP] 1 2 [/SUP], Rafael Gracia[SUP] 3 [/SUP], Elena Piazuelo[SUP] 4 5 6 7 [/SUP], Julián Pardo[SUP] 5 8 9 10 [/SUP], Elena Morte[SUP] 5 10 11 [/SUP], José Ramon Paño[SUP] 5 10 11 [/SUP], Julio Boza[SUP] 3 [/SUP], Patricia Carrera-Lasfuentes[SUP] 4 5 [/SUP], Gustavo A Higuera[SUP] 3 [/SUP], Angel Lanas[SUP] 4 5 12 13 [/SUP]
Affiliations
- PMID: 37081104
- DOI: 10.1038/s41598-023-33682-2
Abstract
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is highly heterogeneous, ranging from asymptomatic to severe and fatal cases. COVID-19 has been characterized by an increase of serum pro-inflammatory cytokine levels which seems to be associated with fatal cases. By contrast, the role of pro-resolving lipid mediators (SPMs), involved in the attenuation of inflammatory responses, has been scarcely investigated, so further studies are needed to understand SPMs metabolism in COVID-19 and other infectious diseases. Our aim was to analyse the lipid mediator metabolome, quantifying pro- and anti-inflammatory serum bioactive lipids by LC-MS/MS in 7 non-infected subjects and 24 COVID-19 patients divided into mild, moderate, and severe groups according to the pulmonary involvement, to better understand the disease outcome and the severity of the pulmonary manifestations. Statistical analysis was performed with the R programming language (R Foundation for Statistical Computing, Vienna, Austria). All COVID-19 patients had increased levels of Prostaglandin E[SUB]2[/SUB]. Severe patients showed a significant increase versus controls, mild- and moderate-affected patients, expressed as median (interquartile range), in resolvin E1 [112.6 (502.7) vs 0.0 (0.0) pg/ml in the other groups], as well as in maresin 2 [14.5 (7.0) vs 8.1 (4.2), 5.5 (4.3), and 3.0 (4.0) pg/ml, respectively]. Moreover, 14-hydroxy docosahexaenoic acid (14-HDHA) levels were also increased in severe vs control and mild-affected patients [24.7 (38.2) vs 2.4 (2.2) and 3.7 (6.4) ng/mL, respectively]. Resolvin D5 was also significantly elevated in both moderate [15.0 (22.4) pg/ml] and severe patients [24.0 (24.1) pg/ml] versus controls [0.0 (0.0) pg/ml]. These results were confirmed by sparse partial least squares discriminant analysis which highlighted the contribution of these mediators to the separation between each of the groups. In conclusion, the potent inflammatory response to SARS-CoV-2 infection involves not only pro- but also anti-inflammatory lipid mediators that can be quantified in easily accessible serum samples, suggesting the need to perform future research on their generation pathways that will help us to discover new therapeutic targets.